News & Publications

The Latest Research and News from Blue Oak

Press Release

Blue Oak taps AI specialist Exscientia for CNS drug discovery

Fund Raising

Viva Biotech Holdings leads Series A funding round, alongside ShangPharma Innovation and JMCR Family Partners, to advance the Blue Oak R&D pipeline in psychiatric drugs


SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Actions


Blue Oak delivers a podium presentation at the Keystone Meeting on Phenotypic Drug Discovery describing a systems neurobiology approach to discovering the next generation of drugs for bipolar depression

Nimh Award

Blue Oak awarded a $900,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH) to develop next generation drugs for bipolar disorder

Join Our Fight Against Brain Disorders

For investment or partnership opportunities or to learn more about our clinical programs, contact our team today.

Contact us